Severe Eosinophilic Asthma clinical trials

Explore recruiting severe eosinophilic asthma clinical trials.

Recruiting severe eosinophilic asthma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Eosinophilic Asthma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma

Spain, Romania, Slovakia, Poland, Germany, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)

Romania, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK)

Sweden, Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)

Poland, Romania, Bulgaria, Czechia, Germany, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Czechia, Spain, Germany, Austria, Lithuania, Hungary +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Severe Eosinophilic Asthma trials by city

Severe Eosinophilic Asthma in Toronto Severe Eosinophilic Asthma in Vancouver Severe Eosinophilic Asthma in Montreal Severe Eosinophilic Asthma in Calgary Severe Eosinophilic Asthma in Edmonton Severe Eosinophilic Asthma in Ottawa Severe Eosinophilic Asthma in Winnipeg Severe Eosinophilic Asthma in Quebec City Severe Eosinophilic Asthma in Hamilton Severe Eosinophilic Asthma in Kitchener Severe Eosinophilic Asthma in London Severe Eosinophilic Asthma in Halifax Severe Eosinophilic Asthma in New York Severe Eosinophilic Asthma in Los Angeles Severe Eosinophilic Asthma in Chicago Severe Eosinophilic Asthma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease